Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | USP1 | O94782 | 3/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2211667 | 0.80 | PSEN1 (0.36) | GRIN1GRIN2BUSP1 | |
| SCHEMBL2211677 | 0.80 | PSEN1 (0.36) | GRIN1GRIN2BUSP1 | |
| SCHEMBL9982892 | 0.79 | FPR2 (0.35) | FPR2SCN9AHTT | |
| SCHEMBL9982933 | 0.76 | GRM2 (0.37) | FPR2SCN9AHTT | |
| SCHEMBL27786403 | 0.75 | HDAC6 (0.34) | USP1 | |
| SCHEMBL9982966 | 0.72 | GRIN1 (0.36) | GRIN1GRIN2B | |
| SCHEMBL2211419 | 0.71 | GRIN1 (0.35) | GRIN1GRIN2BUSP1 | |
| SCHEMBL2209976 | 0.71 | GRIN1 (0.35) | GRIN1GRIN2BUSP1 | |
| SCHEMBL1324380 | 0.70 | BIRC2 (0.34) | GRIN1GRIN2B | |
| SCHEMBL1324377 | 0.70 | BIRC2 (0.34) | GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319614-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319614-A1 | Organic Compounds | XIAP, BIRC5, BIRC3 | GPBAR1 601/4885GRIN1 3077/4885GRIN2B 3299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.